Mereo BioPharma Grp

PDMR Notification

RNS Number : 1267W
Mereo BioPharma Group plc
14 August 2020
 

Mereo BioPharma Group plc

 

PDMR Notification

 

London and Redwood City, Calif ., August 14, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on August 12, 2020 John Richard, Head of Corporate Development of Mereo, purchased 3,500 American Depositary Shares (ADSs) at a price of USD 2.76 per ADS.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 2.76

3,500

 

 

d)

Aggregated information:  volume, Price

 

e)

Date of the transaction

2020-08-12

f)

Place of the transaction

XNMS (Nasdaq Global Market)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGGGDIDDBDGGS